Effect of PD-L1 Expression for the PD-1/L1 Inhibitors on Non-small Cell Lung Cancer: A Meta-analysis Based on...

Area of Science:

• Oncology
• Immunotherapy
• Biomarker Research

Background:

• Programmed death-ligand 1 (PD-L1) expression is a key biomarker in non-small cell lung cancer (NSCLC).
• Tumor proportional score (TPS) quantifies PD-L1 expression, but its predictive value for immunotherapy outcomes requires further exploration.
• Understanding TPS thresholds is crucial for optimizing immune checkpoint inhibitor (ICI) therapy in advanced or metastatic NSCLC.

Approach:

• A meta-analysis synthesized data from 28 randomized controlled trials (RCTs) involving 17,266 participants with advanced or metastatic NSCLC.
• The study evaluated the impact of TPS thresholds (1% and 50%) on overall survival and progression-free survival in patients receiving immunotherapy (PD-1/L1 inhibitors) with or without chemotherapy.
• Subgroup analyses examined treatment efficacy based on TPS levels and combination therapies (ICI + chemotherapy vs. ICI alone).

Key Points:

• Patients with TPS ≥50% demonstrated significantly greater benefits from immunotherapy compared to those with TPS <1%, 1-49%.
• For patients with lower TPS (<1%, 1-49%), combination therapy (ICIs + chemotherapy) showed superior efficacy over ICIs alone.
• Within specific TPS subgroups, PD-1 inhibitors (e.g., pembrolizumab) exhibited better efficacy than PD-L1 inhibitors (e.g., atezolizumab).

Conclusions:

• Tumor proportional score (TPS) is a significant predictive factor for immunotherapy efficacy in advanced or metastatic NSCLC.
• Treatment decisions and selection of specific agents (PD-1 vs. PD-L1 inhibitors, combination vs. monotherapy) should consider TPS levels.
• Further research into TPS-guided immunotherapy strategies may improve patient outcomes in NSCLC.